CERAMENT-BCProject reference: 735144
Funded under :
H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
A novel bone implant with enhanced bone healing capacity
Total cost:EUR 71 429
EU contribution:EUR 50 000
Topic(s):SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs
Funding scheme:SME-1 - SME instrument phase 1
The objective of the project is to bring the first bone implant with enhanced bone healing capacity to the market and clinical practice. The market demand for bone implants is steadily increasing driven by aging populations, increased demand for high quality of life and an increasing number of joint reconstruction surgeries. Enhancement of the bone healing process is often necessary, especially for patients with larger bone voids and gaps. The existing clinical methods targeting this need are based on the combination of Bone Graft Substitutes (BGS) with:
• systemic treatment with Bone Active Drug (BAD), or
• the off-label use of the BAD.
Both alternatives create risks for side-effects and complications.
BONESUPPORT will move beyond the current state of the art and propose CERAMENT-BC – the first product combining a BGS with a BAD (bisphosphonate), enhancing the healing capacity of the implant. The commercial potential of this nano-modified material lies in the efficient local delivery of the drug to the targeted skeletal side, minimizing side-effects and improving quality of life for the patient.
The targeted users are orthopedic surgeons who need new methods for the enhancement of the bone healing process, reduction of secondary fractures and postoperative complications. CERAMENT-BC will meet those needs by combining the advantages of BGS and BAD and thus providing both fracture stability and a local therapeutic effect.
The Phase 1 study will develop a business plan for the commercialisation of the product. Assuring cost-efficient and innovative approaches to the treatment of musculoskeletal conditions is an EU-wide challenge. The project will address this challenge by proposing a new treatment option which for the first time combines an injectable biomaterial with a BAD.
EU contribution: EUR 50 000
223 63 LUND